2013-02-01 15:09:11 - Fast Market Research recommends "Cimzia (Rheumatoid Arthritis) Forecast and Market Analysis" from GlobalData, now available

GlobalData has released its new PharmaPoint Drug Evaluation report, Cimzia (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

UCB's Cimzia is a pegylated Fab' fragment of a humanized anti-TNF IgG molecule which disrupts the inflammatory process. This disruption reduces the rate of progressive joint damage, thus improving physical function. Cimzia is only about

40kDa (kilo Daltons) in size; therefore, this small antibody lacks the ability to cross-link and lacks an Fc region. Clinical evidence suggests that Cimzia maintains similar efficacy and safety to other TNF inhibitors.


Full Report Details at
- www.fastmr.com/prod/532534_cimzia_rheumatoid_arthritis_forecast_ ..


Scope

* Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Cimzia including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Cimzia for the top eight countries from 2012 to 2022.
* Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy and Australia.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Cimzia performance
* Obtain sales forecast for Cimzia from 2011-2022 in US, Japan, UK, France, Germany, Spain, Italy and Australia.

Report Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
4.2 Diagnosis
4.3 Treatment
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Product Profile - Cimzia (certolizumab pegol)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Abbreviations
7.2 Bibliography
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Rheumatoid Arthritis Patients
7.4.2 Percent Drug-treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analysts
7.7.2 Global Head of Healthcare
7.8 About GlobalData
7.9 Contact Us
7.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Product Profile - Cimzia
Table 6: Cimzia SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for Cimzia
Table 8: Physicians Surveyed, By Country

List of Figures

1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Figure 2: Rheumatoid Arthritis Biologic Drug Targets
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
Figure 4: Severity of Rheumatoid Arthritis
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations*

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.